Produktdetaljer
Biografisk notat
James D. Chalmers is Rhodes Chair of Experimental Therapeutics at the University of Oxford (Oxford, UK) and an active clinician caring for patients with difficult respiratory infections, particularly bronchiectasis. Amelia Shoemark is Asthma and Lung UK Chair of Respiratory Research at the University of Dundee (Dundee, UK), where she leads a translational research programme in chronic and rare respiratory disease. Stefano Aliberti is Full Professor of Respiratory Diseases at Humanitas University in Milan (Italy) and Chief of the Respiratory Unit at IRCCS Humanitas Research Hospital (Rozzano, Italy).
Once considered an orphan condition, bronchiectasis is now recognised as a common and actionable chronic respiratory disease with an expanding clinical and research community. The European Respiratory Society (ERS) has taken the lead in this area by supporting the European Multicentre Audit and Research Collaboration (EMBARC), a project that has done much to help understanding of bronchiectasis. In this Monograph, key leaders of EMBARC, James D. Chalmers, Amelia Shoemark and Stefano Alberti, have brought together comprehensive and authoritative chapters covering epidemiology, imaging, current management advice, future therapeutic options, and the challenges to come. This Monograph will provide clinicians, researchers and allied health professionals with the knowledge and tools required to improve the quality of life of people living with bronchiectasis.
This Monograph will provide clinicians, researchers and allied health professionals with the knowledge and tools required to improve the quality of life of people living with bronchiectasis.
- Understanding bronchiectasis through patient voices
- Epidemiology of bronchiectasis
- The basics of bronchiectasis
- Radiology in bronchiectasis: from radiological signs to quantifiable disease
- The immunology of bronchiectasis
- Mucociliary clearance in bronchiectasis
- Chronic airway infection and the microbiome in bronchiectasis
- Primary ciliary dyskinesia
- Allergic bronchopulmonary aspergillosis
- Autoimmune conditions and bronchiectasis
- COPD, asthma and bronchiectasis overlap
- Nontuberculous mycobacterial infections and bronchiectasis
- Investigation and management of immunodeficiency disorders in bronchiectasis
- Protracted bacterial bronchitis and “pre-bronchiectasis”
- Principles of management: an overview of the 2025 European Respiratory
- Society bronchiectasis guidelines
- Airway clearance management in bronchiectasis: techniques, devices and mucoactive agents
- Antibiotic management: macrolides and inhaled antibiotics
- Dipeptidyl peptidase-1 inhibitors in bronchiectasis
- Investigation and management of the deteriorating patient
- Acute exacerbations of bronchiectasis
- Bronchiectasis in children
- Bronchiectasis clinical trial design considerations
- The bronchiectasis treatment pipeline
- What have we learned from the EMBARC project?
- Research priorities and progress for bronchiectasis
Produktdetaljer
Biografisk notat
James D. Chalmers is Rhodes Chair of Experimental Therapeutics at the University of Oxford (Oxford, UK) and an active clinician caring for patients with difficult respiratory infections, particularly bronchiectasis. Amelia Shoemark is Asthma and Lung UK Chair of Respiratory Research at the University of Dundee (Dundee, UK), where she leads a translational research programme in chronic and rare respiratory disease. Stefano Aliberti is Full Professor of Respiratory Diseases at Humanitas University in Milan (Italy) and Chief of the Respiratory Unit at IRCCS Humanitas Research Hospital (Rozzano, Italy).